ClinicalTrials.gg
RecruitingNCT06642623ENVELOPUpdated Oct 15, 2024

A Prospective Trial of Enavogliflozin to Evaluate Cardio-renal Outcome in Type 2 Diabetes Mellitus Patients

A Phase 4 interventional study of Enavogliflozin and Dapagliflozin or Empagliflozin in Diabetes Mellitus, Type 2, Cardiovascular Diseases and Kidney Diseases, sponsored by Yonsei University. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by Yonsei University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Jan 2024, registered Oct 2024).
  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
2,862
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies testing enavogliflozin in Diabetes Mellitus, Type 2 — 7 open to participants now, 8 under way, 4 of them phase 3. Enavogliflozin · Diabetes Mellitus, Type 2.

Planned enrollment
Largest of 15
2,862 · median 140
Started
2024
with 1 other
Phase 4
3 of 15
3 open now
Registered
13th of 15
by date
Lead sponsor
1 of 15
Yonsei University

Among the 15 studies testing enavogliflozin in Diabetes Mellitus, Type 2, this one has the largest planned enrollment, is one of 2 that started in 2024, is one of 3 in phase 4, and was the 13th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 15 studies testing enavogliflozin in Diabetes Mellitus, Type 2 are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

About enavogliflozin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing enavogliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The novel sodium-glucose cotransporter-2 (SGLT2) inhibitor, enavogliflozin, effectively reduces glycated hemoglobin (HbA1c) levels and body weight without increasing the risk of serious adverse events. However, its long-term clinical benefits concerning cardiovascular and renal outcomes have yet to be thoroughly studied. This study is an investigator-initiated, multicenter, randomized, pragmatic, open-label, active-controlled, non-inferiority trial. Eligible participants are adults aged 19 or older with type 2 diabetes who have a history of, or are at risk for, cardiovascular disease. A total of 2,862 participants will be randomly assigned to receive either enavogliflozin or other SGLT2 inhibitors with proven cardiorenal benefits, such as dapagliflozin or empagliflozin. The primary endpoint is the time to the first occurrence of a composite of major adverse cardiovascular and renal events. This trial aims to determine whether enavogliflozin is non-inferior to dapagliflozin or empagliflozin in terms of cardiorenal outcomes in patients with type 2 diabetes and cardiovascular risk factors. It will also clarify role of enavogliflozin in preventing vascular complications in this patient population.

Read the detailed description

The ENVELOP study aims to assess cardiorenal outcomes following enavogliflozin administration compared with dapagliflozin or empagliflozin in Korean patients with type 2 diabetes, representing the first large-scale SGLT2 inhibitor outcome study targeting this population.

03

Conditions studied

  • Diabetes Mellitus, Type 2
  • Cardiovascular Diseases
  • Kidney Diseases
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female adults aged 19 years and older at screening
  2. Subjects diagnosed with T2D at screening
  3. Subjects on treatment with or requiring treatment with enavogliflozin, dapagliflozin, or empagliflozin within the scope of label and reimbursement criteria

Exclusion criteria

Exclusion Criteria:

  1. Subjects with different types of diabetes mellitus other than T2D
  2. Subjects with moderate to severe hepatic impairment
  3. Subjects with to SGLT-2 inhibitors, i.e., kidney function disorders with estimated glomerular filtration () \<60 mL/min/1.73 m2, end stage renal disease (ESRD), or on dialysis
  4. Subjects with major comorbidities
  5. Subjects with a history of to enavogliflozin, dapagliflozin, or empagliflozin and any of its components
  6. Pregnant or breastfeeding women
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,862 participants (estimated)

Study arms

  • Experimental
    Enavogliflozin Group

    Subjects will take Enavogliflozin according to the investigator's judgment.

    Drug: Enavogliflozin

  • Active comparator
    Dapagliflozin, Empagliflozin Group

    Subjects will take Dapagliflozin or Empagliflozin according to the investigator's judgment.

    Drug: Dapagliflozin or Empagliflozin

Interventions

  • The dosage and administration method are determined according to the investigator's judgment, considering the drug's approval requirements and the medical condition of the study participants.

  • DrugDapagliflozin or Empagliflozin

    The dosage and administration method are determined according to the investigator's judgment, considering the drug's approval requirements and the medical condition of the study participants.

06

What researchers measure

Primary outcomes

  1. Time from randomization to first onset of cardiorenal composite outcome event

    Major adverse cardiovascular events include nonfatal myocardial infarction (MI), nonfatal stroke, and hospitalization for unstable angina, hospitalization for heart failure, coronary or peripheral revascularization, and death from any cause. Renal events include a sustained decline in estimated glomerular filtration rate (GFR) calculated by means of the Chronic Kidney Disease Epidemiology Collaboration equation of ≥40% from baseline to \<60 mL/min/1.73m2, onset of end-stage kidney disease (dialysis for ≥28 days, kidney transplantation, or an estimated GFR of \<15 mL/min/1.73m2), development of macroalbuminuria, and death from renal causes.

    Time frame: 6 months, 12 months, 24 months, 36 months and 48 month

Secondary outcomes

  1. Time from randomization to the first onset of 3-point MACE and proportion of the patients

    Time to first event of a composite of key major adverse cardiovascular events (non-fatal MI, non-fatal stroke, and death from cardiovascular causes)

    Time frame: 6 months, 12 months, 24 months, 36 months and 48 months

  2. death from any cause

    Time to death from any cause

    Time frame: 6 months, 12 months, 24 months, 36 months and 48 months

  3. death from cardiovascular causes

    Time to death from cardiovascular cause

    Time frame: 6 months, 12 months, 24 months, 36 months and 48 months

  4. hospitalization due to unstable angina

    Time to first event of hospitalization due to unstable angina

    Time frame: 6 months, 12 months, 24 months, 36 months and 48 months

  5. hospitalization due to heart failure

    Time to first event of hospitalization due to heart failure

    Time frame: 6 months, 12 months, 24 months, 36 months and 48 months

  6. coronary or peripheral revascularization

    Time to first event of coronary or peripheral revascularization

    Time frame: 6 months, 12 months, 24 months, 36 months and 48 months

  7. major renal events

    Time to first event of a composite of major kidney events

    Time frame: 6 months, 12 months, 24 months, 36 months and 48 months

  8. progression of macroalbuminuria

    Time to development of macroalbuminuria

    Time frame: 6 months, 12 months, 24 months, 36 months and 48 months

07

Study locations

1 of 1 sites recruiting
  • Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea
    Seoul, 03722, Korea, Republic of
    Recruiting
    • Bong Soo Cha, MD, PhD · Contactbscha@yuhs.ac · +82-2-2228-1962
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Sep 2029, 68 months after the start.

Of 320 non-industry phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 68 months is above that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2024
First posted
Oct 15, 2024
StartActual
Jan 22, 2024
Primary completionEst.
Sep 30, 2029
CompletionEst.
Dec 31, 2030
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06642623
Lead sponsor
Yonsei University
Responsible party
Sponsor
First posted
Oct 15, 2024
Start date
Jan 22, 2024
Primary completion
Sep 30, 2029 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Oct 15, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enavogliflozin

Start the discussion